33051945
2020 Oct 13.</span
It is unclear whether suboptimal adherence contributes to adverse clinical outcomes in patients with chronic hepatitis B (CHB). Moreover, there is no consensus regarding the optimal level of drug adherence. This was a population-based historical cohort study including 51 975 adult CHB patients treated with entecavir (0.5 mg/d orally). Data were obtained from the Korean national health insurance service claims database, which covers >99% of the entire population, between 2007 and 2015. Medication adherence was categorized as high (proportion of days covered [PDC], â‰¥90%; n = 32 089), intermediate (PDC, 80%-89%; n = 10 197) and low (PDC,
entecavir; hepatitis B virus; hepatocellular carcinoma; mortality; proportion of days covered.
